Faculty

Needs Statement

Smoking remains the leading cause of preventable death in the U.S, and alarmingly, more than 7% of U.S. women smoke during pregnancy. Further, co-use of tobacco and one or more illicit drugs has increased over the past decade, including among pregnant women. In fact, 20% of pregnant women in the U.S. co-use tobacco and cannabis, and 77-95% of pregnant U.S. women with an opioid use disorder also report being a cigarette smoker. Treatment for substance use disorders (SUD) often takes precedent over treatment for tobacco disorders, and less than half of SUD facilities offer tobacco cessation counseling. Importantly, research findings in the area of concurrent treatment reveal that smoking cessation among those with SUD is associated with synergistic benefits including improved mental and physical outcomes. ​However, healthcare providers often cite lack of knowledge and training to provide tobacco treatment among women with SUD, including during pregnancy.

Target Audience

Physicians, Nurses, Physician Assistants, Public Health Professionals, Social Workers

Objectives

Upon completion of this activity, participants will be able to:

1. Describe the prevalence of substance use disorder among women, including pregnant women in the U.S.​
2. State the maternal and fetal or infant health risks associated with perinatal substance use.​
3. Describe the benefits of concurrent tobacco treatment for women, including pregnant women, with SUD.​
4. List evidence-based components of tobacco treatment for women, including pregnant women, with SUD.
5. Describe strategies for overcoming barriers to tobacco treatment. 

 

 

 

Accreditation

In support of improving patient care, University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME
This enduring material is designated for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Other
UK Healthcare CECentral certifies this activity for 1.00 hour of participation.

ASWB ACE
As a Jointly Accredited Organization, UK HealthCare CECentral is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. UK HealthCare CECentral maintains responsibility for this course. Social workers completing this course receive 1.00 clinical continuing education credit.

CNE
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.00 nursing contact hour.

Faculty Disclosure

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

None of the planners, faculty, and others in control of educational content for this educational activity have relevant financial relationship(s) to disclose with ineligible companies.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation. 

 

Acknowledgement

In collaboration with University of Kentucky Perinatal Research and Wellness Center.